Gaps in Persistence, Coverage Limit GLP-1 Impact in Obesity

Why It Matters

Improving GLP‑1 adherence and expanding coverage can enhance weight‑loss outcomes while delivering measurable savings for employers and health‑plan sponsors, addressing a major cost driver in U.S. obesity care.

Key Takeaways

• Persistence drops from 65% at 120 days to 34% at one year.
• Out‑of‑pocket costs ≥$150 double discontinuation risk versus <$42.
• ≥5 clinician visits increase 120‑day persistence 49‑fold.
• Employer coverage of semaglutide yields 1.6:1 ROI, $5.28 PMPM cost.
• PBMs see highest ROI at 2:1, $0.57 PMPM cost.

Pulse Analysis

Real‑world data continue to reveal that GLP‑1 receptor agonists, despite their proven efficacy, suffer from rapid drop‑off in use. The AMCP poster examined over 53,000 initiators of liraglutide, semaglutide and tirzepatide and identified key levers of persistence: affordable out‑of‑pocket pricing and frequent provider interaction. Patients facing $150 or more in co‑pay were markedly more likely to stop therapy, while those with five or more clinician visits were dramatically more adherent, underscoring the role of structured follow‑up in chronic weight‑management programs.

Economic modeling presented at the same meeting quantified the upside of broader coverage. By simulating a five‑year rollout of semaglutide 2.4 mg to one million eligible employees, researchers calculated a 1.6:1 return on investment for employers and net savings for health plans, PBMs and government payers. The model factored in a $1,349 list price per fill, a 63% rebate, and a 10% treatment uptake, translating to a modest $5.28 per‑member‑per‑month cost offset by $8.21 in health‑system savings. Pharmacy benefit managers emerged with the strongest ROI (2:1), driven by reduced obesity‑related comorbidity expenditures.

For managed‑care decision‑makers, the combined evidence points to two actionable pathways: implement adherence‑support initiatives—such as regular provider touchpoints and cost‑sharing subsidies—and negotiate formulary placement that reflects the long‑term fiscal benefits of GLP‑1 therapy. As obesity continues to impose $200‑$370 billion in annual U.S. health costs, aligning clinical guidelines with payer incentives could accelerate adoption, improve patient outcomes, and ultimately curb the economic burden of this chronic disease.